Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Andrew Kuykendall

Andrew Kuykendall

Moffitt Cancer Center

Academic History

Andrew Kuykendall, MD, is an Assistant Member at Moffitt Cancer Center, Tampa, FL, in the Department of Malignant Hematology. In 2012, he earned his medical degree from the University of Florida College of Medicine, Gainesville, FL. In 2015, he completed his Internal Medicine residency at the University of South Florida, Tampa, FL, and in 2018, he finished his Hematology and Medical Oncology fellowship at Moffitt Cancer Center/University of South Florida, Tampa, FL.

Speaking on new disease-modifying therapies for MPNs

Dr Kuykendall’s key research interests lie in myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS)/MPN overlap syndromes and systemic mastocytosis (SM). More specifically, he aims to develop novel and disease-modifying therapies for these diseases and has been the primary investigator of several clinical trials. Dr Kuykendall is an active member of the MPN-Research Consortium, which strives to improve treatment options for patients with MPNs by developing new agents.

Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
Andrew Kuykendall et al. • 16 Jul 2024
Predicting thrombocytopenia as a result of ruxolitinib treatment in MF 1:44
Predicting thrombocytopenia as a result of ruxolitinib treatment in MF
Andrew Kuykendall • 27 Nov 2023
Preliminary results of a Phase II study of fedratinib in patients with MDS/MPN and CNL 2:03
Preliminary results of a Phase II study of fedratinib in patients with MDS/MPN and CNL
Andrew Kuykendall • 27 Nov 2023
Thromboembolic event rates in patients with PV: a real-world analysis 2:06
Thromboembolic event rates in patients with PV: a real-world analysis
Andrew Kuykendall • 27 Nov 2023
Challenges and options for patients with hydroxyurea-resistant PV 1:40
Challenges and options for patients with hydroxyurea-resistant PV
Andrew Kuykendall • 27 Nov 2023
ASH 2023: what to look forward to in the MPN space 1:27
ASH 2023: what to look forward to in the MPN space
Andrew Kuykendall • 27 Nov 2023
Blast-phase MPNs: a major unmet need in the field 1:32
Blast-phase MPNs: a major unmet need in the field
Andrew Kuykendall • 11 Dec 2022
The need for disease-modifying therapies in MPNs 1:39
The need for disease-modifying therapies in MPNs
Andrew Kuykendall • 11 Dec 2022
The current state-of-the-art in MF and PV therapy and future outlooks 2:16
The current state-of-the-art in MF and PV therapy and future outlooks
Andrew Kuykendall • 11 Dec 2022
The challenges of treating patients with MPNs who possess a TP53 mutation 1:13
The challenges of treating patients with MPNs who possess a TP53 mutation
Andrew Kuykendall • 11 Dec 2022
Insights into novel agents and potential combination therapies being explored in MF 1:14
Insights into novel agents and potential combination therapies being explored in MF
Andrew Kuykendall • 11 Dec 2022
Clinical risk factors for disease progression in MPNs
Andrew Kuykendall • 10 Nov 2022
Drivers of progression in MPNs and the importance of early intervention 6:37
Drivers of progression in MPNs and the importance of early intervention
Andrew Kuykendall et al. • 26 Aug 2022
The promise of pelabresib in MF and insights into the MANIFEST-2 study 1:55
The promise of pelabresib in MF and insights into the MANIFEST-2 study
Andrew Kuykendall • 26 Aug 2022
Genetic mechanisms driving thrombocytopenia in MF patients 3:51
Genetic mechanisms driving thrombocytopenia in MF patients
Andrew Kuykendall • 26 Aug 2022
Patient risk stratification in MPNs: current and future approaches 2:40
Patient risk stratification in MPNs: current and future approaches
Andrew Kuykendall • 26 Aug 2022
The content of VJHemOnc is intended for healthcare professionals